Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents

Highlights

• The effect of puberty suppression and cross-sex hormone therapy on bone health in transgender adolescents is unknown.

• P1NP and 1CTP decreased during therapy with GnRHa and were even lower after 24 months of cross-sex hormone therapy.

• The lumbar spine BMAD and Z-scores increased after 24 months of cross-sex hormone therapy in transgender adolescents.

• Added value of BTM measurements seem to be limited, but DXA-scans remain important in follow-up of transgender adolescents.

Abstract

Puberty is highly important for the accumulation of bone mass. Bone turnover and bone mineral density (BMD) can be affected in transgender adolescents when puberty is suppressed by gonadotropin-releasing hormone analogues (GnRHa), followed by treatment with cross-sex hormone therapy (CSHT). We aimed to investigate the effect of GnRHa and CSHT on bone turnover markers (BTMs) and bone mineral apparent density (BMAD) in transgender adolescents. Gender dysphoria was diagnosed based on diagnostic criteria according to the DSM-IV (TR). Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included. Patients were allocated to a young (bone age of < 15 years in transwomen or < 14 in transmen) or old group (bone age of ≥ 15 years in transwomen or ≥ 14 years in transmen). All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16 years. Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol. P1NP, osteocalcin, ICTP and BMD of lumbar spine (LS) and femoral neck (FN) were measured at three time points. In addition, BMAD and Z-scores were calculated. We found a decrease of P1NP and 1CTP during GnRHa treatment, indicating decreased bone turnover (young transmen 95% CI − 74 to − 50%, p = 0.02, young transwomen 95% CI − 73 to − 43, p = 0.008). The decrease in bone turnover upon GnRHa treatment was accompanied by an unchanged BMAD of FN and LS, whereas BMAD Z-scores of predominantly the LS decreased especially in the young transwomen. Twenty-four months after CSHT the BTMs P1NP and ICTP were even more decreased in all groups except for the old transmen. During CSHT BMAD increased and Z-scores returned towards normal, especially of the LS (young transwomen CI 95% 0.1 to 0.6, p = 0.01, old transwomen 95% CI 0.3 to 0.8, p = 0.04). To conclude, suppressing puberty by GnRHa leads to a decrease of BTMs in both transwomen and transmen transgender adolescents. The increase of BMAD and BMAD Z-scores predominantly in the LS as a result of treatment with CSHT is accompanied by decreasing BTM concentrations after 24 months of CSHT. Therefore, the added value of evaluating BTMs seems to be limited and DXA-scans remain important in follow-up of bone health of transgender adolescents.

Introduction

Puberty is the most important period in life regarding the accumulation of bone mass. In general, about 85%–90% of the total bone mass will have been acquired at the end of puberty [1]. Sex steroids reach high concentrations as puberty progresses and play a key role in the augmented bone growth and bone mass accumulation in adolescents. Consequently, the process of bone turnover, bone remodelling and bone mineral apposition increase during puberty as well [2]. In adolescents with gender dysphoria the pubertal development of secondary sex characteristics during puberty can cause psychological distress because this physical maturation belongs to their unwanted sex assigned at birth. When transgender adolescents are treated, the first step of the so-called gender affirming (GA) therapy is the administration of gonadotropin-releasing hormone analogues (GnRHa) to suppress puberty. The GnRHa treatment induces a hypogonadal state, resulting in a developmental arrest of the undesired secondary sex characteristics of the sex assigned at birth [3], [4], [5]. Bone metabolism is affected by the GnRHa treatment as well and as a result the BMD as measured by DXA-scan can decrease [6], [7]. The second step of the GA therapy of transgender adolescents consists of gender affirming hormones also known as cross-sex hormone therapy (CSHT) from the age of 16 years. The purpose of CSHT is to induce the development of secondary sex characteristics of the desired sex. Until now the effects of CSHT on both BMD and bone turnover in transgender adolescents are not known [6], [8], [9].

Bone turnover markers (BTMs) can be used to display the actual bone metabolism in transgender adolescents. Several studies show that BTMs reach high concentrations during biological puberty [10], [11], [12]. To date, there is little data on the course of BTMs in relation to BMD during pubertal suppression and treatment with CSHT in transgender adolescents. When GA therapy affects the bone quality during puberty this might have an impact on the bone quality in later adult life, especially with regard to a possible lower BMD and the risk of osteoporosis and fractures. Hence, studies are needed to assess both the immediate and the long-term effects of the GA therapy on bone metabolism in transgender adolescents.

The objective of this study is to investigate the course of three bone turnover markers in relation to bone mineral density, in transgender adolescents during gonadal suppression and during CSHT.